ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-04: Form 8-K; Period of report 2015-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-11-03: Form 8-K; Period of report 2015-11-03; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2015-08-05: Form 8-K; Period of report 2015-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2015-06-01: Form 8-K; Period of report 2015-05-29; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-04 | 8-K | 2015-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2015, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2015. | t83455_8-k.htm |
| 2015-11-03 | 8-K | 2015-11-03 | 7.01 Regulation FD Disclosure | 7.01 On November 3, 2015, ArQule, Inc. (the “Registrant”) announced that it had exercised its option with Daiichi Sankyo to co-commercialize tivantinib in the United States (the “Co-Commercialization Option”), pursuant to the License, Co-Development and Co-Commercialization Agreement by and between Registrant and Daiichi Sankyo Co., Ltd. dated December 18, 2008 (the “Agreement”). | t83440_8k.htm |
| 2015-08-05 | 8-K | 2015-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2015, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2015. | t82895_8k.htm |
| 2015-06-01 | 8-K | 2015-05-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 29, 2015, the Board of Directors of the Registrant appointed Robert J. Weiskopf as the Registrant’s Chief Financial Officer effective June 1, 2015. | t82463_8k.htm |
| 2015-05-13 | 8-K | 2015-05-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The voting results are set forth in Exhibit 99.1 to this report and incorporated herein by reference. | t82316_8k.htm |
| 2015-05-07 | 8-K | 2015-05-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | t82272_8k.htm |
| 2015-05-06 | 8-K | 2015-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2015, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2015. | t82216_8k.htm |
| 2015-03-04 | 8-K | 2015-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2015, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter and year ended December 31, 2014. | t1500479_8k.htm |